Transient scaffolding using bioresorbable drug-eluting polymeric platforms aims to improve late clinical outcomes through restoration of vasomotion, adaptive shear stress, late plaque regression and expansive remodelling. However, long-term data are scarce. Several studies have reported the midterm comparison of the Absorb™ bioresorbable scaffold (Abbott Vascular, Santa Clara, CA, USA) with its metallic stent counterpart, XIENCE® (Abbott Vascular). Preclinical evaluation has shown that scaffold degradation is complete by 36 months3. The aim of this report is to present the first four-year comparative evaluation after the expected full resorption of the scaffold device.

Additional Metadata
Persistent URL dx.doi.org/10.4244/EIJ-D-17-00873, hdl.handle.net/1765/104613
Journal EuroIntervention
Rights no subscription
Citation
Chevalier, B, Cequier, A, Dudek, D, Haude, M, Carrié, D, Sabaté, M, … Serruys, P.W.J.C. (2018). Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial). EuroIntervention, 13(13), 1561–1564. doi:10.4244/EIJ-D-17-00873